Alto Neuroscience, Inc. Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit
Alto Neuroscience, Inc. (ANRO) reported Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit of $2.44 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit · last filed 2026-08-12
- Alto Neuroscience, Inc. share-based payment arrangement, option, exercise price range, lower range limit for the quarter ending 2026-03-31 was $2.44.
- Alto Neuroscience, Inc. share-based payment arrangement, option, exercise price range, lower range limit for the quarter ending 2025-12-31 was $2.44.
- Alto Neuroscience, Inc. share-based payment arrangement, option, exercise price range, lower range limit for the quarter ending 2025-09-30 was $2.44.
- Alto Neuroscience, Inc. share-based payment arrangement, option, exercise price range, lower range limit for the quarter ending 2025-06-30 was $2.44.
| Period end | Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit 3 month | Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit 6 month |
|---|---|---|
| 2026-06-30 | $2.44 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $2.44 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $2.44 10-K · filed 2026-03-16 | |
| 2025-09-30 | $2.44 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $2.44 10-Q · filed 2025-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |